At our core, we develop immune system modulators that activate and direct the most powerful immune cells in the body for targeted responses to disease. Our underpinning science originates from two of New Zealand’s leading research institutes, the Ferrier Research Institute of Victoria University of Wellington and the Malaghan Institute of Medical Research, who together have been developing novel immune system modulators since 2007.
Key partners –
The Ferrier Research Institute of Victoria University of Wellington. The 27-strong Ferrier Research Institute team was established over 30 years ago and has built a world-class reputation in carbohydrate and complex chemistry. They have a long history in developing compounds that have resulted in significant breakthroughs in medical care. We are working closely with the Ferrier Research Institute’s chemical immunology team, which is also led by one of Avalia’s co-founding scientists, Professor Gavin Painter.
The Malaghan Institute of Medical Research is New Zealand’s leading independent medical research institute employing over 90 staff. They are focused on developing better treatments for disease. Malaghan’s scientists are recognised internationally for their research into the development of more effective immunotherapies and treatments for cancer, asthma and allergy, multiple sclerosis and infectious disease. We work closely with the Vaccine Therapy program, which is also led by Professor Ian Hermans, one of Avalia’s co-founding scientists.
GlycoSyn Limited are Australasia’s premier cGMP manufacturer for the development and production of complex active pharmaceutical ingredients (APIs) for pre-clinical and clinical drug development programmes. GlycoSyn has been supporting international clients since 2003 with an emphasis on conventional small molecules. They work closely with us to ensure synthesis of key components of our drug compounds are scalable and meet strict manufacturing standards and regulatory requirements for pre-clinical and clinical programs.
We collaborate with research institutes and other organizations around the globe to support our discovery efforts, assess combination therapies and to advance our pipeline. We will continue to evaluate new strategic collaborations with academic institutes, government agencies and industry to accelerate clinical translation to ensure meaningful benefits are delivered to patients.